TWYNEO® (tretinoin/BPO)
Acne vulgaris
CommercialActive
Key Facts
About Sol-Gel Technologies
Sol-Gel Technologies' mission is to develop and commercialize advanced topical dermatological therapies using its patented Sol-Gel microencapsulation platform. Its key achievement is the FDA approval and launch of TWYNEO® for acne vulgaris, marking its transition to a commercial entity. The company's strategy combines proprietary development of its pipeline with strategic out-licensing to established dermatology players for commercialization. With a pipeline of 15 candidates targeting acne, rosacea, psoriasis, and other conditions, Sol-Gel aims to build a portfolio of differentiated products in the growing medical dermatology market.
View full company profileTherapeutic Areas
Other Acne vulgaris Drugs
| Drug | Company | Phase |
|---|---|---|
| Pipeline Program | MatriSys Bioscience | Preclinical |
| AKVANO®-based Acne treatment | Lipidor | Pre-clinical/Phase 1 |
| Acne & Impure Skin | Pelpharma Handels | Commercial |
| GM-503 | Galderma Group | Phase 1 |
| CB-03-01 (Cortexolone 17α-propionate) | Cosmo Pharmaceuticals | Phase III |
| SGT-510 | Sol-Gel Technologies | Phase 2 |
| TWYNEO® | Mayne Pharma Group | Marketed |
| TVB-3567 | Sagimet Biosciences | Phase 1 |